Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Betterlife Pharma Inc (CSE: BETR ) 0.1150 UNCHANGED Official Closing Price Updated: 12:49 PM EST, Nov 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Betterlife Pharma Inc < Previous 1 2 Next > BetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001 October 23, 2024 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife Announces Fully Subscribed Private Placement Financing August 29, 2024 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife Highlights Advantages of Non-hallucinogenic LSD Derivative BETR-001 and Publication of its Methods to Treat Mood Disorders Patent August 27, 2024 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife Announces Closing of a Private Placement July 02, 2024 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife To Present BETR-001 Preclinical Data at the 2024 Conference of the Federation of European Neuroscience Societies (FENS) in Vienna, Austria June 26, 2024 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife Announces Closing of a Private Placement June 14, 2024 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001 May 14, 2024 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife Announces Intent to Complete Private Placement of Units May 03, 2024 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife Advances BETR-001 IND-enabling Studies May 01, 2024 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference April 11, 2024 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001 April 03, 2024 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001 January 02, 2024 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University March 04, 2024 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife Announces Closing of a Private Placement December 18, 2023 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife Announces Extension of Warrants November 30, 2023 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife Pharma to Host Investors Update Call on September 18, 2023 September 14, 2023 From BetterLife Pharma Inc. Via GlobeNewswire US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives November 15, 2023 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001 September 12, 2023 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement September 05, 2023 From BetterLife Pharma Inc. Via GlobeNewswire Better Home & Finance Announces Closing of Business Combination August 23, 2023 From Better Home & Finance Via Business Wire BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression and Announces Closing of Private Placement July 13, 2023 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives June 27, 2023 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada June 22, 2023 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife Continues Progress on BETR-001 IND-Enabling Studies June 08, 2023 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California April 25, 2023 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference April 20, 2023 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article March 29, 2023 From BetterLife Pharma Inc. Via GlobeNewswire Promise of BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article March 22, 2023 From BetterLife Pharma Inc. Via GlobeNewswire Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders” March 09, 2023 From BetterLife Pharma Inc. Via GlobeNewswire BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments January 26, 2023 From BetterLife Pharma Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
